On October 22, HBM HOLDINGS-B fell 5.23% in Regular Trading, trading at HK$10.18, with turnover of HK$72.48 million.
The most recent company-specific development in public disclosures was a share buyback on October 20, when the company repurchased 300,000 shares on-market for about HK$3.14 million at HK$10.34 to HK$10.50 per share. The treasury share balance rose to 34.534 million shares, following earlier repurchases of 300,000 shares on October 16 and 700,000 shares on October 15 and October 14.
While these filings indicate continued capital management activity under the approved repurchase mandate, they do not clearly explain the current sell-off. The broader Biotechnology segment was also weak, with AKESO down 7.49%, INNOVENT BIO down 4.1%, BEONE MEDICINES down 1.81%, MICOT PHARMA-B up 11.58%, and EVEREST MED down 5.1%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments